OpiCalc

989 Clinical Tools

ALBI Grade (Liver)ASTCT Grading ATA Thyroid Risk BCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPI CML ELTS Score CNS-IPI CTCAE v5.0 Calvert Formula DIPSS-Plus (Myelofibrosis)Deauville Score EAU NMIBC Risk ECOG Performance Status ELN 2022 Risk (AML)ELN CML Milestones FIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2 Fleischner 2017 Guidelines Fong Clinical Risk Score HCT-CI (Sorror Score)HPV/p16 Oropharynx IGCCCG Risk (Testicular)IMDC (Heng) Criteria IMWG Myeloma Frailty IPSS-M (Molecular MDS)ISUP Grade Groups Karnofsky Status (KPS)Khorana Score Lugano Classification Lung-RADS v2022 MIPI-b (Biological)MRD Assessment Framework MSI/MMR Interpretation Mayo 20/2/20 (SMM)NCCN Prostate Risk NCCN-IPI (DLBCL)NSCLC GPA Oncotype DX Recurrence Opioid Equianalgesic PD-L1 TPS Interpretation PERCIST 2.0 PREDICT v3.0 Platinum-Free Interval R2-ISS (Revised 2)RANO 2.0 RCB (Residual Cancer Burden)RECIST 1.1 ROMA Score SAVER Score SINS Score SLiM-CRAB Criteria Sedlis/Peters Criteria TNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AML Z0011 Eligibility iRECIST iwCLL 2018 Response mRECIST (HCC)mRENAL Score mrTRG (Rectal MRI)

ELN 2022 Risk (AML)

Haematological Malignancies

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

Core-binding factor fusion

NPM1 mutation

In-frame bZIP CEBPA mutation

TP53 mutation

Myelodysplasia-related gene mutation

Adverse cytogenetics

KMT2A rearrangement

RUNX1 mutation

ASXL1 mutation

BCOR mutation

Calculated Interpretation

Intermediate Risk

Intermediate risk includes FLT3-ITD without adverse lesions and non-favorable/non-adverse profiles.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Primary Use

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

Section 2

Formula & Logic

Clinical Inputs

Core-binding factor fusion	Binary clinical feature
NPM1 mutation	Binary clinical feature
In-frame bZIP CEBPA mutation	Binary clinical feature
TP53 mutation	Binary clinical feature
Myelodysplasia-related gene mutation	Binary clinical feature
Adverse cytogenetics	Binary clinical feature
KMT2A rearrangement	Binary clinical feature
RUNX1 mutation	Binary clinical feature
ASXL1 mutation	Binary clinical feature
BCOR mutation	Binary clinical feature

Interpretive Logic

Adverse lesions override favorable markers.

FLT3-ITD without adverse lesions now sits in intermediate risk regardless of allelic ratio.

Core binding factor, mutated NPM1, and bZIP CEBPA patterns remain favorable.

Section 3

Pearls/Pitfalls

Result Bands

Favorable	No adverse lesion and at least one favorable-defining lesion.
Intermediate	Neither favorable nor adverse dominant profile.
Adverse	TP53, MR genes/cytogenetics, or other adverse lesions present.

Section 4

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.

Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

Section 5

Evidence Appraisal

Evidence Base

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

OpiCalc Medical Oncology Module • Haematological Malignancies. 2026;Logic implemented from widely used contemporary oncology classification, prognostic, and response-assessment frameworks.

Section 6

Literature

Context

ELN 2022 Risk (AML) is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.

Last Comprehensive Review: 2026

Related Oncology Tools

CLL-IPI

iwCLL 2018 Response

WHO 2022 / ICC 2022 AML

IPSS-M

MRD Assessment Framework

CML ELTS Score

ELN CML Milestones

Lugano Classification

NCCN-IPI

MIPI-b

Have feedback about this calculator?Let us know.

ELN 2022 Risk (AML)

Haematological Malignancies

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

Core-binding factor fusion

NPM1 mutation

In-frame bZIP CEBPA mutation

TP53 mutation

Myelodysplasia-related gene mutation

Adverse cytogenetics

KMT2A rearrangement

RUNX1 mutation

ASXL1 mutation

BCOR mutation

Calculated Interpretation

Intermediate Risk

Intermediate risk includes FLT3-ITD without adverse lesions and non-favorable/non-adverse profiles.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Primary Use

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

Section 2

Formula & Logic

Clinical Inputs

Core-binding factor fusion	Binary clinical feature
NPM1 mutation	Binary clinical feature
In-frame bZIP CEBPA mutation	Binary clinical feature
TP53 mutation	Binary clinical feature
Myelodysplasia-related gene mutation	Binary clinical feature
Adverse cytogenetics	Binary clinical feature
KMT2A rearrangement	Binary clinical feature
RUNX1 mutation	Binary clinical feature
ASXL1 mutation	Binary clinical feature
BCOR mutation	Binary clinical feature

Interpretive Logic

Adverse lesions override favorable markers.

FLT3-ITD without adverse lesions now sits in intermediate risk regardless of allelic ratio.

Core binding factor, mutated NPM1, and bZIP CEBPA patterns remain favorable.

Section 3

Pearls/Pitfalls

Result Bands

Favorable	No adverse lesion and at least one favorable-defining lesion.
Intermediate	Neither favorable nor adverse dominant profile.
Adverse	TP53, MR genes/cytogenetics, or other adverse lesions present.

Section 4

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.

Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

Section 5

Evidence Appraisal

Evidence Base

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

OpiCalc Medical Oncology Module • Haematological Malignancies. 2026;Logic implemented from widely used contemporary oncology classification, prognostic, and response-assessment frameworks.

Section 6

Literature

Context

ELN 2022 Risk (AML) is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.

Last Comprehensive Review: 2026

Related Oncology Tools

CLL-IPI

iwCLL 2018 Response

WHO 2022 / ICC 2022 AML

IPSS-M

MRD Assessment Framework

CML ELTS Score

ELN CML Milestones

Lugano Classification

NCCN-IPI

MIPI-b

Have feedback about this calculator?Let us know.